

13
76. (New) The chimeric protein of claim 75 which is selected from the group consisting of F_{PIV-3} - F_{RSV} , F_{RSV} - HN_{PIV-3} and F_{PIV-3} - G_{RSV} hybrid genes.

In the Drawings:

Cancel the informal drawings submitted with the application and substitute therefor the formal drawings enclosed.

REMARKS

The disclosure has been amended to correspond to the changes made to the parent application.

Formal drawings have been substituted for the informal drawings. It is noted that Figure 5 has been amended as shown on the enclosed print of the original drawing in red, to correct a spelling error. The Sequence Listing enclosed herewith, both in hard copy and computer-readable form, includes the changes effected in the drawings.

It is hereby stated that the hard copy and computer-readable form of the Sequence Listing are the same.

The claims have been amended in the interests of expedited prosecution. In this regard, it is noted that the definition of the chimeric protein is the same as allowed in the diagnostic claims of the parent case. The claims directed to the hybrid gene and method of making the chimeric protein recombinantly utilizes corresponding language.

The PTO-1449 submitted herewith lists all prior art cited by or to the PTO in the parent and related filings. Copies of each of the references are enclosed for the Examiner's convenience.

Respectfully submitted,

Mark L

M.I. Stewart
Reg. No. 24,973

Toronto, Ontario, Canada,
(416) 595-1155
FAX No. (416) 595-1163